Investor relations

With the marketing approval for Sedaconda (isoflurane) in 15 EU countries and a great interest in inhaled sedation and our products, Sedana Medical is well-positioned for the future.

We are well on the way to the vision of making inhaled sedation a standard therapy in critical care.

Johan Spetz

CFO and Head of Investor Relations Send Email

The Share

See More

Press Releases

Sedana Medical secures data exclusivity and market protection for Sedaconda[®] (isoflurane) until 2031


Sedana Medical AB (publ) announces that the European Medicines Agency’s Paediatric Committee has iss…

Key results of Sedana Medical’s paediatric study IsoCOMFORT published


Sedana Medical AB (publ) today announces that the main results from the paediatric IsoCOMFORT study…

Sedana Medical AB’s Interim report January-September 2023


All-time-high Q3 sales and further steps towards ex-US profitability

View All Press Releases

Financial Calendar

Year-End Report 2023 15 February 2024 07:00
Annual Report 2023 15 April 2024 07:00

See More